Implantica Publishes Interim Report for Q1 2026
Implantica has released its interim report for the first quarter of 2026, highlighting significant advancements in the clinical outcomes and economic impact of its product, RefluxStop®, a CE-marked implant for treating gastroesophageal reflux disease (GERD). The company will hold a teleconference on May 22, 2026, featuring key executives to discuss the report. Implantica focuses on innovative implantable technologies and has a range of products alongside RefluxStop® that support remote monitoring and wireless powering of implants.
VADUZ, Liechtenstein, May 22, 2026 /PRNewswire/ — Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStop® Significant events in the first quarter of 2026 Secured over EUR 1.2 million in new multi-year public tender approvals in Italy, further strengthening…
